The Pharmaceutical Care Management Association (PCMA) had an independent third party conduct a survey of its members to assess the potential impact on monthly premiums for Medicare Prescription Drug Plans (PDPs) if all drug manufacturer rebates and pharmacy direct and indirect remuneration (DIR) were required to be applied at the point of sale (POS) starting next year.
Six PCMA member companies with more than 14.6 million PDP enrollees in 2018 responded to the survey, which was conducted in January 2018.
View the Survey
